Merck (MRK) Construction in Progress (2009 - 2025)
Merck (MRK) posted quarterly Construction in Progress of $9.2 billion for Q4 2025, up 14.8% year-over-year from $8.0 billion in Q4 2024, and up 14.8% quarter-over-quarter from $8.0 billion in Q4 2024.
Merck (MRK) Construction in Progress (2009 - 2025) Analysis & Trends
Merck (MRK) has reported Construction in Progress for 17 consecutive years, with $9.2 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Construction in Progress rose 14.8% year-over-year to $9.2 billion; the TTM figure through Dec 2025 stood at $9.2 billion (up 14.8% YoY), while the FY2025 annual figure was $9.2 billion, up 14.8% from the prior year.
- Construction in Progress advanced to $9.2 billion in Q4 2025 per MRK's latest filing, from $8.0 billion in the prior quarter.
- Across five years, Construction in Progress topped out at $9.2 billion in Q4 2022 and bottomed at $8.0 billion in Q4 2024.
- Historically, Construction in Progress has averaged $8.6 billion across 5 years, with a median of $8.3 billion in 2021.
- Annual changes were most pronounced in 2021 — Construction in Progress rose 19.3% — and 2023, when it retreated 10.06%.
- Merck's Construction in Progress stood at $8.3 billion in 2021, then rose by 10.5% to $9.2 billion in 2022, then decreased by 10.06% to $8.3 billion in 2023, then decreased by 3.36% to $8.0 billion in 2024, then rose by 14.8% to $9.2 billion in 2025.
- Business Quant data shows MRK's Construction in Progress at $9.2 billion in Q4 2025, $8.0 billion in Q4 2024, and $8.3 billion in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | - |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | - |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 7.98 Bn |
| Dec 31, 2023 | 8.26 Bn |
| Dec 31, 2022 | 9.19 Bn |
| Dec 31, 2021 | 8.31 Bn |
| Dec 31, 2020 | 6.97 Bn |
| Dec 31, 2019 | 5.01 Bn |
| Dec 31, 2018 | 3.36 Bn |
| Dec 31, 2017 | 2.30 Bn |
| Dec 31, 2016 | 1.87 Bn |
| Dec 31, 2015 | 1.53 Bn |
| Dec 31, 2014 | 1.45 Bn |
| Dec 31, 2013 | 1.81 Bn |
| Dec 31, 2012 | 2.44 Bn |
| Dec 31, 2011 | 2.20 Bn |
| Dec 31, 2010 | 2.07 Bn |
| Dec 31, 2009 | 1.82 Bn |